The estimated Net Worth of Efthymios Deliargyris is at least $839 millier dollars as of 13 December 2023. Dr Deliargyris owns over 22,557 units of Cytosorbents Corp stock worth over $348,433 and over the last 6 years he sold CTSO stock worth over $0. In addition, he makes $490,112 as Chief Medical Officer at Cytosorbents Corp.
Sign up
Dr D CTSO stock SEC Form 4 insiders trading
Dr has made over 1 trades of the Cytosorbents Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 22,557 units of CTSO stock worth $30,001 on 13 December 2023.
The largest trade he's ever made was buying 22,557 units of Cytosorbents Corp stock on 13 December 2023 worth over $30,001. On average, Dr trades about 2,256 units every 0 days since 2018. As of 13 December 2023 he still owns at least 348,433 units of Cytosorbents Corp stock.
You can see the complete history of Dr Deliargyris stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. biography
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. is the Chief Medical Officer at Cytosorbents Corp.
What is the salary of Dr D?
As the Chief Medical Officer of Cytosorbents Corp, the total compensation of Dr D at Cytosorbents Corp is $490,112. There are 5 executives at Cytosorbents Corp getting paid more, with Phillip Chan having the highest compensation of $1,404,380.
How old is Dr D?
Dr D is 53, he's been the Chief Medical Officer of Cytosorbents Corp since . There are 9 older and 2 younger executives at Cytosorbents Corp. The oldest executive at Cytosorbents Corp is Dr. Robert H. Bartlett, 82, who is the Co-Chairman of Cardiac Surgery Advisory Board & Consultant.
What's Dr D's mailing address?
Efthymios's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Insiders trading at Cytosorbents Corp
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus et Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
What does Cytosorbents Corp do?
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
What does Cytosorbents Corp's logo look like?
Complete history of Dr Deliargyris stock trades at Cytosorbents Corp et PLx Pharma
Cytosorbents Corp executives and stock owners
Cytosorbents Corp executives and other stock owners filed with the SEC include:
-
Phillip Chan,
President, Chief Executive Officer, Director -
Vincent Capponi,
Chief Operating Officer -
Kathleen Bloch,
Chief Financial Officer -
Dr. Phillip P. Chan,
CEO & Director -
Vincent J. Capponi M.S., MS,
Pres & COO -
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.,
Chief Medical Officer -
Kathleen P. Bloch CPA, M.B.A., MBA, CPA,
CFO & Sec. -
Al Kraus,
Independent Non-Executive Chairman of the Board -
Alan Sobel,
Independent Director -
Edward Jones,
Independent Director -
Michael Bator,
Independent Director -
Dr. Robert H. Bartlett,
Co-Chairman of Cardiac Surgery Advisory Board & Consultant -
Christopher Cramer,
VP of Bus. Devel. -
Dr. Christian Steiner M.D.,
Exec. VP of Sales & Marketing -
Terri Anne Powers M.B.A.,
VP of Investor Relations & Corp. Communications -
Peter J Mariani,
Chief Financial Officer -
Eric R. Mortensen,
Chief Medical Officer -
Robert Hawes Bartlett,
Chief Medical Officer -
Investment Fund, Lp Njtc,
10% owner -
Joseph Rubin,
Director -
Ronald Berger,
Interim CFO -
James T. Gunton,
Director -
Efthymios Deliargyris,
Chief Medical Officer -
Jiny Kim,
Director